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Abstract
DNA methylation is the most studied epigenetic modification due to its role in regulating gene expression, and its
involvement in the pathogenesis of cancer and several diseases upon aberrations in methylation. The method of choice
to evaluate genome-wide methylation has been the Illumina HumanMethylation450 BeadChip (450K), but it was recently
replaced with the MethylationEPIC BeadChip (EPIC). We therefore sought to validate the EPIC array in comparison to the
450K array for both fresh-frozen (FF) and formalin-fixed paraffin-embedded (FFPE) tumours. We also performed analysis on
the EPIC array with paired FF and FFPE samples to adapt to a clinical setting where FFPE is routinely used. Further, we
compared two restoration methods, REPLI-g and Infinium, for FFPE-derived DNA on the EPIC array.
The Pearson correlation of β values for common probes on the 450K and EPIC array was high for both FF (mean: 0.992)
and FFPE (mean: 0.984) samples. The β values generated from the EPIC array for FFPE samples correlated well with the
paired FF tumours, but varied between 0.901 and 0.987. We did note that sample pairs with lower correlation had less
bimodal density distributions of β values and displayed higher noise in the copy number alteration plots (generated
from the methylation array data) in the FFPE sample. Both REPLI-g and the Infinium restoration for FFPE samples
performed well on the EPIC array and generated equivalent correlation scores to the paired FF sample.
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Introduction
DNA methylation is the most studied epigenetic mark,
as it is crucial for cell development and regulation of
gene expression with aberrations involved in the patho-
genesis of several diseases including cancer [1]. DNA
methylation is the addition of a methyl group to the car-
bon-5 position of cytosine, which in mammals primarily
takes place on cytosine-phosphate-guanine (CpG) dinucleo-
tides. Several CpG sites clustering in close proximity are
termed CpG islands, which are most frequently located in
gene promoter regions inferring that unmethylated CpG
islands allow for transcription whereas hypermethylated
promoter regions repress gene expression [2]. DNA methy-
lation aberrations, e.g. in the form of hypermethylation of
the promoter of a tumour-supressing gene, are common in
cancer, including paediatric brain tumours, and methylation
profiling is an increasingly valuable tool when it comes to
tumour classification [3–5]. The Illumina HumanMethyla-
tion450 BeadChip (450K), covering 485,000 CpG sites, has
been the most common method to assess genome-wide
methylation [6], but this array has now been discontinued
and replaced with the MethylationEPIC BeadChip (EPIC)
which covers 850,000 CpG sites [7].
The use of DNA methylation profiling to classify and
subgroup paediatric brain tumours is now moving into
clinical diagnostics where the golden standard for
histopathological assessments and archiving material is
formalin-fixed paraffin-embedded tissue (FFPE). While
FFPE is excellent for this purpose, it does induce
problems with extraction of nucleotides as the formalin-
fixation causes cross-linking and fragmentation of the
DNA thus yielding degraded DNA of poor quality [8].
This degradation renders the DNA unsuitable for whole
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genome amplification (WGA), a vital step in Illumina
methylation arrays, thus preventing the use of methyla-
tion arrays on FFPE samples. However, two different
methods for DNA restoration produced satisfying results
for FFPE samples using the 450K arrays [9–11]. To
ascertain the transferability to the EPIC arrays, we have
compared paediatric brain tumour samples that were
analysed with the 450K and the EPIC arrays; both fresh-
frozen (FF) and FFPE samples, thereby reporting the first
validation of FFPE samples between the platforms. The
EPIC array has thus far been validated in comparison
with the 450K platform only for cell lines and blood
samples [12] and merely one paired sample (renal
tumour) of FF and FFPE [7]. We therefore also assessed
the accuracy of the EPIC array by comparing nine paired
FF and FFPE brain tumour samples and also performed
the first comparison on the EPIC array of the two
aforementioned protocols for DNA restoration; REPLI-g
[9] and Infinium [10].
Results
This study evaluates the performance of the newly
released EPIC platform in comparison to 450K in brain
tumour samples. As the analysis of methylation in the
clinical setting often is performed on FFPE samples
rather than FF, we also evaluated the performance of the
EPIC array on nine FFPE samples and compared with
the paired FF sample of the same tumour. Further, we
assessed two different restoration protocols for the FFPE
samples; all nine were restored with REPLI-g, and four
of them were also restored with Infinium. The full
experimental setup is displayed in Fig. 1. All data is
publicly available at GEO; accession number GSE92580.
First, we compared the β values for the ~425,000 CpG
sites that are present on both the 450K and the EPIC
array for nine FF samples, and three FFPE samples.
DNA from the same batch was used for both array types.
Density plots of the β values for the common probes
(Fig. 2a, b) displayed similar distribution between the
arrays for FF and FFPE and good quality for all
samples. The Pearson correlation between the 450K
and EPIC array ranged between 0.988 (p < 2.2 · 10−16) and
0.996 (p < 2.2 · 10−16) for the FF samples (mean correl-
ation: 0.992, std: 0.003, Fig. 2c) and between 0.980 and
0.989 for FFPE (mean correlation: 0.984, std: 0.005,
Fig. 2d), confirming previously published results in other
tissues that the EPIC array stably reproduces results from
the 450K platform also for brain tumours [7, 12].
We proceeded with comparing nine paired FF and
FFPE samples on the EPIC array to adapt to a clinical
setting where FFPE samples are routinely used. Density
plots of the β values displayed some variation, with a
tendency for the FFPE samples to indicate worse quality
than the FF samples by displaying higher density in the
middle-range β values (Fig. 3a). The Pearson correlation
between paired FF and FFPE samples ranged from 0.901
to 0.987 (p < 2.2 · 10−16) for the nine included tumours,
with a mean value of 0.938 (std: 0.028, Fig. 3b, c) thus
confirming the usability of analysing FFPE samples on
the EPIC array. Differences between FF and FFPE
samples are expected and well documented in several
studies [9, 11, 13] because of the fragmented state and
poor quality of FFPE-derived DNA. While the restoration
Fig. 1 Experimental setup. a Nine fresh-frozen (FF) paediatric brain tumour samples (tumours T01-T09) were processed on the Illumina 450K and EPIC array
to compare the platforms. Nine formalin-fixed paraffin-embedded (FFPE) samples paired to the FF samples were analysed on the EPIC array to assess the
correlation between FF and FFPE and thereby the suitability of the array in a clinical setting (FFPE samples). Four of the FFPE samples (tumours T01, T06, T08,
T09) were restored with both the REPLI-g and Infinium protocol to enable comparison between the methods. b Three FFPE samples (tumours T10-T12),
restored with REPLI-g, were analysed with the 450K as well as the EPIC array to compare the platforms for FFPE samples
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procedures render DNA of sufficient quality for methyla-
tion arrays (in particular the WGA step in the process), it
does not reach the highest quality of FF-derived DNA. Al-
though some FF-FFPE pairs displayed high correlation in β
values, we also observed two tumours with as low correl-
ation as 0.90. The tendency for these samples were similar,
indicating that the main effect (Fig. 3b) is that a large por-
tion of CpG sites measured as highly methylated in the FF
samples have lost methylation in the FFPE sample. We cal-
culated the ratio between the number of CpG sites with β
values in the low-middle range (between 0.2 and 0.4) and
the number of CpG sites measured on the array, and we
found the ratio to correlate with how well the matched
FFPE and FF samples correlated (Fig. 3d). We did not ob-
serve any clear correspondence between correlation of FF
vs FFPE with neither the age of the FFPE sample nor the
quality of the FFPE-derived DNA, measured as delta CT
value (compared to QC template) with the Illumina FFPE
QC kit (data not shown). Although the age range (14–
45 months) of our samples might be too short to notice
any clear effects from storage, other studies also report no
significant correlation between age of FFPE samples and
the performance of methylation arrays [9, 11, 13]. To fur-
ther compare the FF samples to FFPE, we performed
estimation of copy number alterations (CNAs) based on
the methylation arrays, using the R package conumee. We
did observe a trend of correspondence between noise
estimation of the FFPE copy number readouts (as supplied
by conumee), and how well the β values for FFPE samples
correlated with its matched FF sample (Fig. 3e). The copy
number profile of FFPE sample T1 with the lowest
correlation to the matched FF sample (0.901) displayed a
high noise level (Fig. 3f, lower panel) compared to the cor-
responding FF CNA profile (Fig. 3f, upper panel). For the
samples with high correlation between FF and FFPE, the FF
and FFPE CNA profiles were similar (Fig. 3g). This
indicated that visual inspection of CNA plots could aid in
the assessment of the quality of FFPE samples.
To investigate the distribution of CpG sites that had
differing β values in the FF samples compared to the
FFPE samples, we specifically analysed all sites with a
difference in β value above 0.2 between FF and FFPE
samples from the same tumour. For each CpG site, we
counted how many of the nine sample pairs that had a β
difference >0.2. Very few of the differing sites (268) were
present in all nine tumour FF-FFPE pairs, suggesting
that CpG sites were affected at random in the FFPE
samples making it impossible to predict which sites that
Fig. 2 Validation of the EPIC array for fresh-frozen and formalin-fixed paraffin-embedded tumour samples. Density plot of β values for common
probes in the 450K and EPIC arrays for a fresh-frozen (FF) and b formalin-fixed paraffin-embedded (FFPE) tumour samples. c Pearson correlation
between obtained β values from the 450K and EPIC arrays for common probes of a FF sample (range: 0.988–0.996, mean: 0.992, std: 0.003, n = 9)
and d FFPE sample (range: 0.980–0.989, mean: 0.984, std: 0.005, n = 3)
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are affected when not using paired samples. These 268
differing sites present in all nine samples were spread
evenly over the chromosomes.
Finally, we compared two different DNA restoration
protocols; REPLI-g and Infinium (see Methods). The
main difference between the two restoration protocols is
that REPLI-g is performed before bisulfite conversion
while the Infinium restoration method is applied after
conversion. However, a previous study on the 450K array
has compared REPLI-g restoration performed before vs
after bisulfite conversion with similar correlation scores
to paired FF samples [11]. We compared REPLI-g and
Infinium restoration procedures on four FFPE samples
before processing on the EPIC array. We observed that
the REPLI-g method tends to display higher density
in the middle-range β values (Fig. 3a) than the sam-
ples processed with the Infinium method, suggesting
lower quality in the REPLI-g-restored samples. To
further evaluate the performance, we counted the
number of failed probes in each sample (Table 1),
which were lower in the REPLI-g-restored samples
and calculated the correlation to the matched FF
sample from the same tumour as summarised in
Table 2. Both restoration methods were suitable for
restoring FFPE-derived DNA and generating β values
similar to the FF samples as observed by the mean
correlations; 0.946 (std: 0.037) with REPLI-g and
0.940 (std: 0.037) with Infinium. The correlation to
the FF sample was slightly increased using REPLI-g in
two of the cases, the Infinium method was perform-
ing better in one case, and in one case the
correlation to FF was the same. These ambiguous re-
sults make it hard to argue for either method, al-
though the REPLI-g has the pro of a less time-
consuming protocol and lower cost.
Conclusions
We have investigated the performance of the new EPIC
array compared to the 450K array for brain tumour
samples, as well as evaluated the concordance in β
values with the EPIC platform between FF and FFPE
samples, thus adapting to a clinical setting where FFPE
is the standard preservation method of tissue. We also
evaluated two different DNA restoration protocols for
FFPE samples. To conclude, the reproducibility of 450K
data using the EPIC array is good for both FF and FFPE
brain tumour samples. The EPIC array, like its predecessor,
generates β values from restored FFPE samples similar to
those of the paired FF samples. We note, however, that the
correlation between paired FF and FFPE samples varies,
Fig. 3 Correlation between paired fresh-frozen and formalin-fixed paraffin-embedded tumour samples on the EPIC array. a Density plot of β
values from the EPIC array for fresh-frozen (FF) and formalin-fixed paraffin-embedded (FFPE) samples restored with either Infinium or REPLI-g.
Correlation of β values between paired FF and FFPE paediatric brain tumour samples illustrating the sample with b the lowest and c the highest
Pearson correlation respectively. d Pearson correlation between paired FF and FFPE samples plotted against the proportion of CpG sites with β
values in the low-middle range (between 0.2 and 0.4). e Pearson correlation between paired FF and FFPE samples plotted against a noise
estimate from FFPE copy number alterations (CNAs) indicating a trend of worse correlation with increasing noise. CNA plots for the FF
(upper panel) and paired FFPE sample (lower panel) with f the lowest and g the highest Pearson correlation respectively.
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where noise in the FFPE CNA plot and higher density in
the low-mid range (0.2-0.4) region can be an indication of
bad quality in the FFPE sample. Further, both evaluated
DNA restoration methods yield satisfying results from
FFPE samples on the EPIC array with very similar mean
correlation scores to the matched FF samples. We can
therefore not see any clear benefit for choosing one method
over the other as both are suitable for the purpose
of restoring FFPE-derived DNA for analysis on the
EPIC array.
Materials and methods
Samples
Tumour tissue was obtained from children who under-
went brain tumour surgery at Sahlgrenska University
Hospital 2013–2015 after signed informed consent from
the parents. Part of the tumour tissue was preserved as
FF in liquid nitrogen and part of it as FFPE. FFPE
samples were processed according to standard proce-
dures at the department of Pathology at Sahlgrenska
University Hospital by fixation in 4% formaldehyde for
24 or 48 h (depending on the size of the tissue) prior to
dehydration with increasing ethanol concentrations and
xylene before paraffin infiltration and embedment.
DNA isolation and quality control
DNA from FF tumours was extracted with the
DNeasy Blood & Tissue Kit (69504, Qiagen, Hilden,
Germany) according to the manufacturer’s instruc-
tions with the addition of lysing the samples with the
QIAGEN TissueLyser. FFPE samples (1–3 years old)
were sectioned, and DNA was isolated using QIAamp
DNA FFPE Tissue Kit (56404, Qiagen) according to
manufacturer’s recommendations except de-waxing
steps with Xylene was repeated twice, and the tissue
was digested overnight. DNA concentration was
determined with the Qubit® Fluorometer (Life
technologies). The quality of the DNA extracted from
FFPE samples was assessed in triplicates with the
real-time PCR-based Illumina FFPE QC kit (WG-321-
1001, Illumina, Inc., San Diego, CA) according to the
provided protocol. FFPE samples with delta CT < 3
compared to the QC template (supplied in kit) was
deemed eligible for restoration with REPLI-g or Infi-
nium restoration kit.
DNA restoration—REPLI-g
DNA from FFPE samples was restored either with (1)
REPLI-g prior to bisulfite conversion or (2) with the
Infinium restoration kit after bisulfite modification (see
below). 1 μg FFPE DNA was used for REPLI-g restor-
ation as described previously [9]. For four out of the
nine tumours with paired FF and FFPE, we performed
restoration with REPLI-g and Illumina to compare the
restoration procedures.
Bisulfite conversion
500 ng FF DNA, 1 μg REPLI-g-restored FFPE DNA and
1 μg-unrestored FFPE DNA (for restoration with the
Infinium kit after bisulfite conversion) was used for
bisulfite conversion with the EZ DNA methylation kit
(D5001, Zymo Research, Orange, CA) according to the
manufacturer’s instructions using the alternative incuba-
tion conditions recommended for the Illumina Infinium
methylation arrays. Successful conversion was verified by
control PCR reactions with a primer set specific for bi-
sulfite-converted DNA, and a primer set for uncon-
verted DNA.
DNA restoration—Infinium
All of eluate 1 of the bisulfite-converted unrestored
FFPE DNA (n = 4 samples) was used for restoration with
the Infinium HD FFPE DNA Restore Kit (WG-321-1002,
Illumina) using the Infinium HD FFPE Restore Protocol
supplied by the manufacturer.
Genome-wide methylation arrays
Infinium HumanMethylation450 BeadChips and
Infinium MethylationEPIC BeadChips (Illumina) were
used for the determination of methylation levels of more
than 450,000 and 850,000 CpG sites, respectively, as
previously described [14]. 4 μl of eluate 1 of the FF-,
REPLI-g-restored and Infinium-restored bisulfite-converted
DNA was used for the methylation arrays according to
Table 2 Comparison of REPLI-g and Infinium DNA restoration of
FFPE samples analysed on the EPIC array
Sample FF vs FFPE REPLI-g (r) FF vs FFPE Infinium (r)
T01 0.902 0.920
T06 0.931 0.902
T08 0.962 0.950
T09 0.987 0.987
Mean 0.946 0.940
Pearson correlation for β values from four formalin-fixed paraffin-embedded
(FFPE) paediatric brain tumour samples, restored with REPLI-g and Infinium,
compared with paired fresh-frozen (FF) samples processed on the EPIC array
(p < 2.2 · 10−16 for all sample pairs)
Table 1 Number of failed probes (p > 0.01) in samples
Sample FF FFPE REPLI-g FFPE Infinium
T01 903 6159 10922
T06 640 1004 6372
T08 874 995 2448
T09 398 316 391
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Illumina’s protocols. Unrestored FFPE DNA was not proc-
essed on the methylation arrays.
Data analysis
Raw methylation data was normalised using Noob-
normalisation with the R minfi package [15–17]. CpG
sites with detection p value >0.01 were regarded as failed
and were assigned as missing. Also, 43,254 CpG sites
with probes identified to be cross-hybridizing according
to Pidsley et al. [12] were removed prior to analysis. For
the comparisons between the 450K and EPIC arrays, we
analysed probes present on both platforms. CNA
analysis was performed using the conumee R package
[18]. As reference samples for the CNA analysis, we
used EPIC array data from three samples of non-
malignant tissue-associated fibroblasts (NAF), and five
samples of infant blood from archival Guthrie cards
available in the public GEO dataset: GSE86831.
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